Clinical trials: Tumor Gastric
Esophageal Cancer, Gastric Cancer
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005599
- Testing
- bryostatin 1, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Solid Cancers
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Colorectal Cancer, Solid Cancers, Gastric Cancer
- Trial name
- NCT05396300
- Testing
- Intraperitoneal infusion of FAST CEA-targeted CAR-T, CEA CAR-T cells
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Weijia Fang, MD
Stomach Cancer, Neoplasm Metastasis
Metastatic Gastric Cancer FFCD 03-07
The purpose of this study is to compare the effectiveness of 2 different sequences of polychemotherapy among carrying patients of a adenocarcinoma of the stomach or cardia locally advanced or metastatic.
- Trial name
- NCT00374036
- Testing
- ECC, FOLFIRI
- Where
- France
- Volunteers
- 416 people
- Sponsor
- University Hospital, Toulouse
Gastric Cancer
Handgrip Strength (HGS) With HGS Asymmetry Are Associated With All-cause Mortality and Hospital Readmissions
Adding the handgrip strength (HGS) asymmetry to the existing measurements of low HGS may improve the assessment of muscle function.
- Trial name
- NCT05397444
- Testing
- No intervention
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Nanjing Medical University
Gastric Cancer
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
This study aims to evaluate safety and efficacy of nivolumab (anti-PD-1 antibody), which is approved as tertiary therapy, and neoadjuvant short-term limited local radiotherapy in patients with unresectable recurrent gastric…
- Trial name
- NCT03453164
- Testing
- Radiotherapy, Nivolumab
- Where
- Japan
- Volunteers
- 41 people
- Sponsor
- Fukushima Medical University
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Elderly, S-1
Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer
Stomach cancer is the most common malignant disease and the second most common cause of cancer-related deaths in the Korea. The elderly are primarily affected by the disease with most gastric cancer-related deaths occuring in…
- Conditions
- Elderly, S-1, Oxaliplatin, First-Line
- Trial name
- NCT00961077
- Testing
- S-1 (TS-1) and Oxaliplatin (Oxalitin)
- Volunteers
- 36 people
- Sponsor
- Soonchunhyang University Hospital
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer
- Trial name
- NCT00237900
- Testing
- Gefitinib, 5-fluorouracil, leucovorin and radiotherapy
- Where
- Finland
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma
This anchored matching-adjusted indirect comparison (MAIC) evaluates the relative efficacy of fruquintinib-paclitaxel (using IPD from the FRUTIGA trial, n=703) versus ramucirumab-paclitaxel (using published AgD from RAINBOW-Asia…
- Conditions
- Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Fruquintinib, Ramucirumab
- Trial name
- NCT07144995
- Testing
- Fruquintinib+Paclitaxel, Ramucirumab+Paclitaxel
- Volunteers
- 1,143 people
- Sponsor
- Sun Yat-sen University
Gastroesophageal Adenocarcinoma, First Line Therapy
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA).
- Conditions
- Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer, PDL-1
- Trial name
- ZANGEA (NCT07176312)
- Testing
- Zanidatamab, Pembrolizumab, mFOLFOX
- Where
- 20 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CMG901.
- Conditions
- Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer
- Trial name
- NCT04805307
- Testing
- CMG901
- Where
- 32 sites in China
- Volunteers
- 176 people
- Sponsor
- Keymed Biosciences Co.Ltd
Gastric Cancer With Peritoneal Dissemination
An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II
It is planned to conduct an open-label, prospective, randomized clinical study of the efficacy, tolerability and safety of a single intraperitoneal administration of the investigational drug Prospidelong at a dose of 4000 mg…
- Trial name
- ИНТЕЛОН-02 (NCT06232434)
- Testing
- Prospidelong, chemotherapy
- Where
- Belarus
- Volunteers
- 120 people
- Sponsor
- Research Institute for Physical Chemical Problems of the Belarusian State University
Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
A randomized controlled phase II study exploring first-line treatment options for recurrent/metastatic MSI-H gastric cancer
- Trial name
- NCT07127822
- Testing
- Iparomlimab and Tuvonralimab, First line chemotherapy plus PD-1/PD-L1 antibody
- Where
- 10 sites in China
- Volunteers
- 106 people
- Sponsor
- Peking University
Stomach Neoplasm
The Origin of Infrapyloric Artery
Infrapyloric artery(IPA) is of great importance for gastric cancer patients. According to previous study, the origin of IPA varies greatly among different studies.
- Trial name
- IPA-Origin (NCT03071237)
- Testing
- Gastrectomy
- Where
- China
- Volunteers
- 429 people
- Sponsor
- Peking University
Gastric Cancer
Multi-Omics Noninvasive Inspection of TumOr Risk for Gastric Cancer
This is a prospective, case-control study intended to develop and validate a blood-based multi-omics assay and computational model for early detection of gastric cancer.
- Trial name
- MONITOR- GAC (NCT04947995)
- Testing
- ctDNA multi-omics test
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GeneCast Biotechnology Co., Ltd.
Helicobacter Pylori, Eradication
The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
Recently, the preventive effect of Helicobacter pylori (Hp) eradication treatment on the incidence of gastric cancer has been reported.
- Conditions
- Helicobacter Pylori, Eradication, Gastric Cancer, Medical Care Cost
- Trial name
- NCT00596401
- Where
- Japan
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Showa Inan General Hospital
Gastric Cancer
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.
- Trial name
- NCT02461407
- Testing
- Anlotinib
- Where
- 38 sites in China
- Volunteers
- 378 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed Malignant Solid Neoplasm
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
- Trial name
- NCT05865002
- Testing
- AUR107
- Where
- 37 sites in India
- Volunteers
- 50 people
- Sponsor
- Aurigene Discovery Technologies Limited
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence
This phase II trial tests how well concentrating heated (hyperthermic) chemotherapy in the area that contains the abdominal organs (intraperitoneal [IP]) at the time of surgery works in treating patients with gastric or…
- Conditions
- Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT07139951
- Testing
- Biopsy Procedure, Biospecimen Collection, Cisplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Esophageal Cancer, Gastric Cancer
Laparoscopic Ultrasound Guided Tissue Sampling in Patients With Cancer of the Upper Gastrointestinal Tract
Laparoscopic Ultrasound (LUS) is an important part of the pre-treatment evaluation of patients with upper gastrointestinal tract cancer (esophageal, gastric, pancreatic and liver cancer).
- Conditions
- Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Liver Cancer
- Trial name
- NCT00511264
- Where
- Denmark
- Volunteers
- 250 people
- Sponsor
- Odense University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.